This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
His lab had just developed base editing, a gene-editing approach that makes single-letter changes in DNA and can shut down proteinproduction using strategies including installing a stop signal in the genetic code. They then administered the AAVs to mice infected with the human prion protein.
Together, these attributes provide a strong foundation for protein expression with enough adaptability to produce much of the commercial and therapeutic protein market. Skilled CDMOs can also locate or create favourable genomic microenvironments where transcription factors are efficiently recruited, further boosting proteinproduction.
Messenger RNAs with multiple “tails” could lead to more effective therapeutics By Corie Lok March 22, 2024 Breadcrumb Home Messenger RNAs with multiple “tails” could lead to more effective therapeutics Scientists have engineered long lasting mRNAs that increased therapeutic proteinproduction in cells and animals.
To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase. Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. Drugs that target polymerase could potentially treat Ebola virus infections and save lives.
Peroxisomal metabolic coupling improves fatty alcohol production from sole methanol in yeast. Optogenetic closed-loop feedback control of the unfolded protein response optimizes proteinproduction. How to build a virus-proof cell. Metabolic Engineering. ACS Synthetic Biology. Bundell S & Howe NP.
The virus SARS-CoV-2 emerged in Wuhan, home of a premiere research institute that focuses on viruses. An altered virus could have escaped. Evidence that the virus emerged, or escaped, from the wildlife trade is lacking. Her points: 1. Coincidence? I’ve never thought so. RaTG13 shares about 96.1%
Then, during graduate school at the California Institute of Technology in the early 1960s, he was introduced to bacteriophage T7, a virus that infects Escherichia coli bacteria. Driven by basic biology Studier grew up in Iowa and became fascinated with biophysics while an undergraduate at Yale University.
The newly identified anti-COVID-19 Spike protein VNARs block infection of the virus (in live viral assays) at doses as low as 200 pM, equivalent to the best reported antibodies and much better than many.
Using the obtained sequencing data, Kao Corporation was able to produce an antibody sample in one week using proteinproduction technology such as enzymes cultivated by our technology. Comment from Fumiharu Muroga, Growth Manager at Real Tech Fund]
“Proteins are an important structural component of living things.
Read *An engineered influenza virus to deliver antigens for lung cancer vaccination. Read Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies. Read Maximizing proteinproduction by keeping cells at optimal secretory stress levels using real-time control approaches.
Read *An engineered influenza virus to deliver antigens for lung cancer vaccination. Read Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies. Read Maximizing proteinproduction by keeping cells at optimal secretory stress levels using real-time control approaches.
Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. The deal will provide Biogen the rights to use the technology across their portfolio of gene therapy products.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content